A Tokushima University-spinoff startup developing digital dental crown technology that treats teeth without grinding healthy enamel. By designing crowns that only replace necessary parts, it provides solutions to dental clinics, with adoption at 250 clinics nationwide, contributing to reduced patient costs and improved treatment precision.
徳島大学発スタートアップの株式会社amidex（本社：徳島県徳島市、代表取締役：伊原 晃、以下amidex）は、このたびプレシリーズAラウンドにおいて、総額1.2億円の資金調達（エクイティ）を実施いたしました。こ...
[画像1: https://prtimes.jp/i/147339/6/resize/d147339-6-26d436e0f36f046a5fd8-3.png ] 導入歯科医院数が、全国で250院を突破した「Amidex(TM)」。 株式会社amidex 創立2周年のご挨拶 株式会社amidex（本社：...
株式会社amidex（本社：徳島県徳島市、代表取締役CEO：伊原晃、以下amidex）は、2025年2月18日・19日に開催された「Industry Co-Creationサミット FUKUOKA 2025（ICC FUKUOKA 2025）デザイン&イノベーション...
[画像: https://prtimes.jp/i/147339/2/resize/d147339-2-b1e06671dfdc76b62a57-0.jpg ] 東京科学大学 田上順次名誉教授東京科学大学 田上順次名誉教授 顧問就任について 田上先生は、1995年から2021年まで東京...
株式会社amidex（本社：徳島県徳島市、代表取締役CEO：伊原晃、以下amidex）は、株式会社産学連携キャピタルよりシードラウンドの資金調達（金額非公表）を実施したことをお知らせします。 今回の資金調達に...
Solving challenges in manufacturing, construction, and infrastructure with proprietary AI that leverages even limited data. A startup supporting operational efficiency and labor savings, aiming for a future where humans and AI coexist.
We manufacture and sell rehabilitation devices using virtual reality that provide measurements useful for diagnosis and treatment, or that are used to evaluate task achievement levels.
We are a biotech company leveraging technologies from the National Cerebral and Cardiovascular Center, Nagasaki University, and Osaka University. We are developing "BROTHERS," a proprietary technology that pairs a PNA strand with an antisense oligonucleotide (ASO). This PNA acts as a "safeguard" to significantly reduce the toxicity issues common in conventional oligonucleotide therapeutics. We drive growth through a dual-engine business model: advancing our in-house pipeline for intractable diseases and out-licensing our platform via collaborations with pharmaceutical companies.
Optogenetics is an innovative neural photostimulation technology, with significant contributions from Japanese researchers whose expertise is highly regarded worldwide. Close collaboration with Nagoya Institute of Technology and Kyoto University is advancing the development of high-sensitivity rhodopsins specialized for vision restoration. This technology overcomes the longstanding issue of insufficient light sensitivity in the field of vision restoration. Furthermore, through joint research with Keio University School of Medicine, applied research on the foundational technology is progressing toward the practical realization of the world’s first gene therapy for vision restoration. The goal is to offer new treatment options for patients suffering from blindness or severe visual impairments.
